On June 11, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) reported that the United States Patent and Trademark Office (USPTO) has granted Xspray two new patents in the United States for its product candidates HyNap-Sora and HyNap-Nilo (Press release, Xspray, JUN 11, 2019, View Source [SID1234649564]). The new patents are Xspray’s sixth and seventh product patents, respectively, in the United States, which is Xspray’s main market. The new patents will expire January 11, 2033.
"The new patents for HyNap-Sora and HyNap-Nilo make it significantly more difficult for our competitors to copy upcoming products from our unique platform technology. The patents are also essential for our ability to do good business deals and they strengthen our position in the US market," says Per Andersson, CEO of Xspray.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new patents, US 10,314,829 and US 10,314,830 respectively, cover the pharmaceutical compositions of the company’s product candidates HyNap-Sora and HyNap-Nilo. Xspray is a product company with a broad portfolio of drug candidates in the same substance class that can be reformulated using the same technology platform.

At the end of 2018, Xspray was granted an additional patent for HyNap-Dasa for the US market. This patent, along with these two new ones, are strong and broad composition patents which relate to solid amorphous forms of the active substance. The original products for Dasatinib, Sorafinib and Nilotinib, had total US sales exceeding USD 2 billion in 2018.